Silica nanoparticles induce pulmonary damage in rats via VEGFC/D–VEGFR3 signaling-mediated lymphangiogenesis and remodeling

Yu, Yanan; Pan, Yujie; Chang, Bing; Zhao, Xiaoxu; Qu, Kunlong; Song, Yuguo

doi:10.1016/j.tox.2023.153552

Cited by 2 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 10 Silicon dioxide nanoparticles (SiNPs) are extensively employed as drug carriers for enhancing the efficacy of drug delivery and retention. An investigation by Yu et al 96 assessed the possible toxicity of SiNPs in the lungs and found a significant increase in inflammation and permeability in rat lungs with elevated concentrations of SiNPs, accompanied by lymphatic endothelial cell injury and increased pulmonary lymphangiogenesis and remodeling. This study provides evidence of SiNP-induced lung injury and illustrates the possible drawbacks of SiNPs as carriers for pulmonary drug delivery.…”

Section: Pharmacokinetics and Toxicology Of Inhaled Nano-formulationsmentioning

confidence: 99%

Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review

Feng,

Shi,

Zhang

et al. 2024

IJN

View full text Add to dashboard Cite

Lungs experience frequent interactions with the external environment and have an abundant supply of blood; therefore, they are susceptible to invasion by pathogenic microorganisms and tumor cells. However, the limited pharmacokinetics of conventional drugs in the lungs poses a clinical challenge. The emergence of different nano-formulations has been facilitated by advancements in nanotechnology. Inhaled nanomedicines exhibit better targeting and prolonged therapeutic effects. Although nano-formulations have great potential, they still present several unknown risks. Herein, we review the (1) physiological anatomy of the lungs and their biological barriers, (2) pharmacokinetics and toxicology of nanomaterial formulations in the lungs; (3) current nanomaterials that can be applied to the respiratory system and related design strategies, and (4) current applications of inhaled nanomaterials in treating respiratory disorders, vaccine design, and imaging detection based on the characteristics of different nanomaterials. Finally, (5) we analyze and summarize the challenges and prospects of nanomaterials for respiratory disease applications. We believe that nanomaterials, particularly inhaled nano-formulations, have excellent prospects for application in respiratory diseases. However, we emphasize that the simultaneous toxic side effects of biological nanomaterials must be considered during the application of these emerging medicines. This study aims to offer comprehensive guidelines and valuable insights for conducting research on nanomaterials in the domain of the respiratory system.

show abstract

Section: Pharmacokinetics and Toxicology Of Inhaled Nano-formulationsmentioning

confidence: 99%